Ankylosing Spondylitis Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Ankylosing Spondylitis Market: By Drug Class Type (NSAIDs, TNF inhibitors, and Others), Distribution Channel (Hospital Pharmacy, Retail pharmacy, and Online pharmacy), and Region (North America, Europe, Asia Pacific, Latin America, And MEA) And Forecast To 2028

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Ankylosing Spondylitis Market size is expected to be valued at USD 5,460.5 million in 2022 which is expected to grow at a CAGR of 4.8% over 2022-2028. Ankylosing Spondylitis is a type of arthritis that affects the spine producing long-lasting inflammation of the shoulder, spine, and hip joints. As spondylitis advances between the spine and ribs joint, it ultimately limits the chest movement making it hard to breathe suitably. Advance stages of ankylosing spondylitis cause fractures of the vertebrae. The symptoms include pain in the chest, sensitivity at the pelvis base, tiredness, swelling, and pain in a toe or finger which is usually seen in the age group of 17 to 45 years or late adolescence. Presently, there is no precise treatment for ankylosing spondylitis, but some of medications and cures can relieve the symptoms and help in pain management. The rising prevalence can lead to the ankylosing spondylitis market growth . Moreover, the presence of biologics testing in the market and growing options for the treatment of ankylosing spondylitis are some primary factors that can boost the global ankylosing spondylitis market. Apart from these, increasing awareness among people about new diagnostic approaches can also accelerate the market in the future. Increasing public and private funding for the enhancement of healthcare sectors and strong drugs in the pipeline can also drive the global market further. However, some factors such as the absence of active drugs for the treatment, and the lack of skilled professionals in low-middle income developing countries can restrain the growth of the market. high treatment costs can hinder market growth. Companies should focus on reimbursement policies for ankylosing spondylitis that can create an opportunity for the ankylosing spondylitis market share.

 

Recent Market Developments:

In June 2020, it was found that Simponi (golimumab), a TNF inhibitor is one of the effective therapies for the treatment of ankylosing spondylitis.

In February 2020, Health Canada approved Taltz (ixekizumab) for curing patients with ankylosing spondylitis and who are not responding to traditional therapy.

Ankylosing Spondylitis Market

MARKET SUMMARY
-
4.8%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 4.8%
  • Largest Market– Asia Pacific
  • Fastest Growing Market– North America

Ankylosing Spondylitis Market

  • The global ankylosing spondylitis market report gives a comprehensive outlook across the globe with particular emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.
  • The report on the global ankylosing spondylitis market gives historical, current, and future market sizes based on drug class type, distribution channel, and region.
Key Players
  • AbbVie, Inc,
  • Amgen, Inc,
  • Gilead Sciences
  • Eli Lilly and Company
  • Janssen Pharmaceuticals
Ankylosing Spondylitis Market Dynamics

One of the major reasons for the global ankylosing spondylitis market growth is the increasing prevalence of ankylosing spondylitis. It is a disease that cannot be cured completely however, the symptoms can be handled with physical exercise and drug treatment. For instance, in the case of pain management related to ankylosing spondylitis, NSAIDs are used. disease-modifying antirheumatic drugs (DMARDs), corticosteroids, and TNF inhibitors are used for managing the inflammation caused by this disease. Moreover, the use of monoclonal antibodies for the treatment of disease has been approved which is expected to propel the growth of the market in the forecast period.


North-America Got Significant Share

Ankylosing Spondylitis Market

North America is dominating the global ankylosing spondylitis market growth, due to the presence of global key players in the region and increasing funding from public and private sectors. Moreover, the growing acceptance of different treatment options for curing ankylosing spondylitis has also attributed to the growth of the market. In addition, Asia Pacific is one of the most profitable regions and is generating new prospects for global players. An increase in patient population and an increase in government initiatives to improve the healthcare sectors in order to improve the quality care of the patients suffering from ankylosing spondylitis has the potential to increase the demand for ankylosing spondylitis in these regions.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The ankylosing spondylitis market report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and startup details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Ankylosing Spondylitis Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The primary factors that drive the market are the presence of biosimilars, usage of novel products, and increasing prevalence of ankylosing spondylitis.

AbbVie, Inc, Amgen, Inc, Eli Lilly and Company, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co. Inc, Novartis AG, Pfizer, Inc., Reliance Life Sciences Pvt. Ltd, UCB, Inc. are the key players of the market.

North America is dominating the ankylosing spondylitis market.

Retail pharmacy placed under the distribution channel type segment is the fastest-growing segment of the market.


Report

Table Of Content

1. Executive Summary
2. Global Ankylosing Spondylitis Market Introduction
2.1. Global Ankylosing Spondylitis Market – Taxonomy
2.2. Global Ankylosing Spondylitis Market –Definitions
2.2.1. Drug Class Type
2.2.2. Distribution Channel Type
2.2.3. By Region
3. Global Ankylosing Spondylitis Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Ankylosing Spondylitis Market Dynamic Factors – Impact Analysis
3.6. Global Ankylosing Spondylitis Market – Competition Landscape
3.7. Epidemiology
4. Global Ankylosing Spondylitis Market Analysis, 2017-2021 and Forecast, 2022-2028
4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Ankylosing Spondylitis Market, By Drug Class Type, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1. NSAIDs
5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. TNF inhibitors
5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Others
5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Ankylosing Spondylitis Market, By Distribution Channel Type, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1. Hospital pharmacy
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Retail pharmacy
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Online pharmacy
6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Ankylosing Spondylitis Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1. North America
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Ankylosing Spondylitis Market – Opportunity Analysis Index, By Drug Class Type, By Distribution Channel Type, and Region, 2022-2028
8. North America Ankylosing Spondylitis Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.1. Drug Class Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. NSAIDs
8.1.2. TNF inhibitors
8.1.3. Others
8.2. Distribution Channel Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Hospital pharmacy
8.2.2. Retail pharmacy
8.2.3. Online pharmacy
8.3. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America Ankylosing Spondylitis Market – Opportunity Analysis Index, By Drug Class Type, By Distribution Channel Type, and Country, 2022-2028
8.5. North America Ankylosing Spondylitis Market Dynamics – Trends
9. Europe Ankylosing Spondylitis Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.1. Drug Class Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. NSAIDs
9.1.2. TNF inhibitors
9.1.3. Others
9.2. Distribution Channel Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Hospital pharmacy
9.2.2. Retail pharmacy
9.2.3. Online pharmacy
9.3. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Rest of Europe
9.4. Europe Ankylosing Spondylitis Market – Opportunity Analysis Index, By Drug Class Type, By Distribution Channel Type, and Country, 2022-2028
9.5. Europe Ankylosing Spondylitis Market Dynamics – Trends
10. Asia-Pacific Ankylosing Spondylitis Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
10.1. Drug Class Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. NSAIDs
10.1.2. TNF inhibitors
10.1.3. Others
10.2. Distribution Channel Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Hospital pharmacy
10.2.2. Retail pharmacy
10.2.3. Online pharmacy
10.3. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Ankylosing Spondylitis Market – Opportunity Analysis Index, By Drug Class Type, By Distribution Channel Type, and Country, 2022-2028
10.5. Asia-Pacific Ankylosing Spondylitis Market Dynamics – Trends
11. Latin America Ankylosing Spondylitis Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
11.1. Drug Class Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. NSAIDs
11.1.2. TNF inhibitors
11.1.3. Others
11.2. Distribution Channel Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Hospital pharmacy
11.2.2. Retail pharmacy
11.2.3. Online pharmacy
11.3. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of Latin America
11.4. Latin America Ankylosing Spondylitis Market – Opportunity Analysis Index, By Drug Class Type, By Distribution Channel Type, and Country, 2022-2028
11.5. Latin America Ankylosing Spondylitis Market Dynamics – Trends
12. Middle East and Africa Ankylosing Spondylitis Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
12.1. Drug Class Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. NSAIDs
12.1.2. TNF inhibitors
12.1.3. Others
12.2. Distribution Channel Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Hospital pharmacy
12.2.2. Retail pharmacy
12.2.3. Online pharmacy
12.3. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. South Africa
12.3.3. Rest of MEA
12.4. MEA Ankylosing Spondylitis Market- Opportunity Analysis Index, By Drug Class Type, By Distribution Channel Type, and Country, 2022-2028
12.5. MEA Ankylosing Spondylitis Market Dynamics – Trends
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Key Drug Class Types, Key Developments, Strategies, and SWOT Analysis)
13.2.1. AbbVie, Inc,
13.2.2. Amgen, Inc,
13.2.3. Eli Lilly and Company
13.2.4. Gilead Sciences
13.2.5. Janssen Pharmaceuticals
13.2.6. Merck & Co. Inc
13.2.7. Novartis AG
13.2.8. Pfizer, Inc
13.2.9. Reliance Life Sciences Pvt. Ltd
13.2.10. UCB, Inc.
14. Research Methodology
15. Key Assumptions and Acronyms

Report

Company Profile

  • AbbVie, Inc,
  • Amgen, Inc,
  • Eli Lilly and Company
  • Gilead Sciences
  • Janssen Pharmaceuticals
  • Merck & Co. Inc
  • Novartis AG
  • Pfizer, Inc
  • Reliance Life Sciences Pvt. Ltd
  • UCB, Inc.

Description

Ankylosing Spondylitis Market size is expected to be valued at USD 5,460.5 million in 2022 which is expected to grow at a CAGR of 4.8% over 2022-2028. Ankylosing Spondylitis is a type of arthritis that affects the spine producing long-lasting inflammation of the shoulder, spine, and hip joints. As spondylitis advances between the spine and ribs joint, it ultimately limits the chest movement making it hard to breathe suitably. Advance stages of ankylosing spondylitis cause fractures of the vertebrae. The symptoms include pain in the chest, sensitivity at the pelvis base, tiredness, swelling, and pain in a toe or finger which is usually seen in the age group of 17 to 45 years or late adolescence. Presently, there is no precise treatment for ankylosing spondylitis, but some of medications and cures can relieve the symptoms and help in pain management. The rising prevalence can lead to the ankylosing spondylitis market growth . Moreover, the presence of biologics testing in the market and growing options for the treatment of ankylosing spondylitis are some primary factors that can boost the global ankylosing spondylitis market. Apart from these, increasing awareness among people about new diagnostic approaches can also accelerate the market in the future. Increasing public and private funding for the enhancement of healthcare sectors and strong drugs in the pipeline can also drive the global market further. However, some factors such as the absence of active drugs for the treatment, and the lack of skilled professionals in low-middle income developing countries can restrain the growth of the market. high treatment costs can hinder market growth. Companies should focus on reimbursement policies for ankylosing spondylitis that can create an opportunity for the ankylosing spondylitis market share.

 

Recent Market Developments:

In June 2020, it was found that Simponi (golimumab), a TNF inhibitor is one of the effective therapies for the treatment of ankylosing spondylitis.

In February 2020, Health Canada approved Taltz (ixekizumab) for curing patients with ankylosing spondylitis and who are not responding to traditional therapy.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX